UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 47

Sortiert nach

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.e121-e123

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

Investigational new drugs, 2021-08, Vol.39 (4), p.1081-1088

2021

Link zum Volltext

Verfügbarkeit prüfen

How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?

Cancers, 2023-05, Vol.15 (10), p.2836

2023

Link zum Volltext

Verfügbarkeit prüfen

IκBα targeting promotes oxidative stress-dependent cell death

Journal of experimental & clinical cancer research, 2021-04, Vol.40 (1), p.136-136, Article 136

2021

Link zum Volltext

Verfügbarkeit prüfen

SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

Frontiers in oncology, 2020-08, Vol.10, p.1722-1722

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Cells (Basel, Switzerland), 2022-10, Vol.11 (20), p.3226

2022

Link zum Volltext

Verfügbarkeit prüfen

Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer

Drugs (New York, N.Y.), 2012-06, Vol.72 (Suppl 1), p.37-52

2012

Link zum Volltext

Verfügbarkeit prüfen

Single agent VS-6766 or VS-6766 plus defactinib in KRAS -mutant non-small-cell lung cancer: the RAMP-202 phase II trial

Future oncology (London, England), 2022-05, Vol.18 (16), p.1907-1915

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeted therapy in small cell lung cancer: A new era?

Lung cancer (Amsterdam, Netherlands), 2017-06, Vol.108, p.252-253

2017

Link zum Volltext

Verfügbarkeit prüfen

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Clinical cancer research, 2024-03, Vol.30 (5), p.959

2024

Link zum Volltext

Verfügbarkeit prüfen

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

Cancer treatment reviews, 2021-12, Vol.101, p.102308-102308, Article 102308

2021

Link zum Volltext

Verfügbarkeit prüfen

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2018-10, Vol.23 (10), p.1133-e112

2018

Link zum Volltext

Verfügbarkeit prüfen

Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer: Management of Non-Small Cell Lung Cancer: Focus on Erlotinib

Drugs (New York, N.Y.), 2012, Vol.72, p.37-52

2012

Link zum Volltext

Verfügbarkeit prüfen

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

Lung cancer (Amsterdam, Netherlands), 2021-07, Vol.157, p.85-91

2021

Link zum Volltext

Verfügbarkeit prüfen

Improving lung cancer outcomes through smoking cessation: the Women Against Lung Cancer in Europe (WALCE) experience

Journal of thoracic disease, 2020-07, Vol.12 (7), p.3877-3882

2020

Link zum Volltext

Verfügbarkeit prüfen

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

Critical reviews in oncology/hematology, 2022-04, Vol.172, p.103639-103639, Article 103639

2022

Link zum Volltext

Verfügbarkeit prüfen

A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome

Tumori, 2024-05, p.3008916241255485-3008916241255485

2024

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary management of non small cell lung cancer (NSCLC) in stage III: clinical case description. Recommendations and state of the art

Clinical management issues, 2013-03, Vol.7 (1), p.5-16

2013

Link zum Volltext

Verfügbarkeit prüfen

Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave

Critical reviews in oncology/hematology, 2021-01, Vol.157, p.103189-103189, Article 103189

2021

Link zum Volltext

Verfügbarkeit prüfen

Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer

BMJ open, 2019-02, Vol.9 (2), p.e025483-e025483

2019

Link zum Volltext

Verfügbarkeit prüfen

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Lung cancer (Amsterdam, Netherlands), 2018-06, Vol.120, p.34-45

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(45)
Buchkapitel
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(33)
Oncology
(29)
Humans
(20)
Lung Cancer
(15)
Respiratory System
(11)
Lung Neoplasms - Drug Therapy
(10)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(9)
Lung Neoplasms - Pathology
(8)
Aged
(7)
Chemotherapy
(7)
Female
(7)
Non-Small Cell Lung Cancer
(7)
Middle Aged
(6)
Carcinoma, Non-Small-Cell Lung - Genetics
(5)
Carcinoma, Non-Small-Cell Lung - Pathology
(5)
Lung Neoplasms - Genetics
(5)
Male
(5)
Mesothelioma
(5)
Mutation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Crizotinib in MET -Deregulated or ROS1 -Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC

Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma

How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?

IκBα targeting promotes oxidative stress-dependent cell death

Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach

SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit

Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer

Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience

Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer

Single agent VS-6766 or VS-6766 plus defactinib in KRAS -mutant non-small-cell lung cancer: the RAMP-202 phase II trial

Targeted therapy in small cell lung cancer: A new era?

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial

Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon

NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer

Emerging New Agents for the Management of Patients with Non-Small Cell Lung Cancer: Management of Non-Small Cell Lung Cancer: Focus on Erlotinib

Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era

Improving lung cancer outcomes through smoking cessation: the Women Against Lung Cancer in Europe (WALCE) experience

A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma

A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome

Multidisciplinary management of non small cell lung cancer (NSCLC) in stage III: clinical case description. Recommendations and state of the art

Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave

Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer

Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma

Suchergebnisse filtern